Revolution Medicines (RVMD) Competitors $40.79 -1.19 (-2.83%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$41.10 +0.31 (+0.76%) As of 06/11/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RVMD vs. BNTX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, and VTRSShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Revolution Medicines vs. Its Competitors BioNTech Beigene Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking. Does the MarketBeat Community prefer RVMD or BNTX? BioNTech received 48 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 78.03% of users gave Revolution Medicines an outperform vote while only 47.04% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes10378.03% Underperform Votes2921.97% BioNTechOutperform Votes15147.04% Underperform Votes17052.96% Do insiders & institutionals believe in RVMD or BNTX? 94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor RVMD or BNTX? In the previous week, BioNTech had 18 more articles in the media than Revolution Medicines. MarketBeat recorded 19 mentions for BioNTech and 1 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.94 beat BioNTech's score of 0.56 indicating that Revolution Medicines is being referred to more favorably in the media. Company Overall Sentiment Revolution Medicines Positive BioNTech Positive Do analysts prefer RVMD or BNTX? Revolution Medicines currently has a consensus price target of $67.08, suggesting a potential upside of 64.46%. BioNTech has a consensus price target of $138.25, suggesting a potential upside of 31.09%. Given Revolution Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Revolution Medicines is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has more risk & volatility, RVMD or BNTX? Revolution Medicines has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Which has better earnings & valuation, RVMD or BNTX? BioNTech has higher revenue and earnings than Revolution Medicines. BioNTech is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$742K10,239.72-$436.37M-$4.00-10.20BioNTech$2.75B9.23$1.01B-$3.40-31.02 Is RVMD or BNTX more profitable? Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% BioNTech -15.16%-2.35%-2.05% SummaryBioNTech beats Revolution Medicines on 11 of the 19 factors compared between the two stocks. Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMD vs. The Competition Export to ExcelMetricRevolution MedicinesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.60B$3.09B$5.57B$8.61BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-11.3633.3227.1720.06Price / Sales10,239.72469.84409.72157.10Price / CashN/A168.6838.2534.64Price / Book3.683.457.064.70Net Income-$436.37M-$72.35M$3.23B$247.88M7 Day Performance1.47%6.23%2.89%2.66%1 Month Performance-2.60%16.53%9.06%6.40%1 Year Performance2.00%-16.90%31.40%14.07% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDRevolution Medicines4.4448 of 5 stars$40.79-2.8%$67.08+64.5%+4.5%$7.60B$742K-11.36250Positive NewsBNTXBioNTech2.8468 of 5 stars$113.10+18.0%$140.14+23.9%+6.7%$27.19B$2.75B-53.863,080Analyst RevisionHigh Trading VolumeONCBeigene1.3592 of 5 stars$245.93+0.1%$319.00+29.7%N/A$24.41B$4.18B-29.859,000Trending NewsInsider TradeTEVATeva Pharmaceutical Industries4.0928 of 5 stars$17.26+2.8%$24.50+42.0%-0.3%$19.56B$16.62B-11.9036,800ITCIIntra-Cellular Therapies0.9353 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.7507 of 5 stars$21.77+3.9%$39.17+79.9%-17.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics2.9648 of 5 stars$17.73-2.7%$37.40+110.9%+159.7%$13.17B$700K-63.32110Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeRDYDr. Reddy's Laboratories1.4815 of 5 stars$14.73+0.0%$17.00+15.4%+10.6%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.5456 of 5 stars$175.69+7.9%$216.07+23.0%+30.2%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.5173 of 5 stars$27.05+1.8%$53.58+98.1%-81.3%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.508 of 5 stars$8.69-1.1%$10.50+20.8%-15.6%$10.20B$14.33B-11.7437,000 Related Companies and Tools Related Companies BNTX Alternatives ONC Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVMD) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
